The proto-oncogene Myc drives expression of the NK cell-activating NKp30 ligand B7-H6 in tumor cells

References

• Cerwenka A, Lanier LL. Natural killer cells, viruses and cancer. Nat Rev Immunol 2001; 1:41-9; PMID:11905813; http://dx.doi.org/10.1038/35095564
   PubMed Web of Science ®Google Scholar
• Kaifu T, Escaliere B, Gastinel LN, Vivier E, Baratin M. B7-H6/NKp30 interaction: a mechanism of alerting NK cells against tumors. Cell Mol Life Sci 2011; 68:3531-9; PMID:21877119; http://dx.doi.org/10.1007/s00018-011-0802-7
   PubMed Web of Science ®Google Scholar
• Raulet DH, Guerra N. Oncogenic stress sensed by the immune system: role of natural killer cell receptors. Nat Rev Immunol 2009; 9:568-80; PMID:19629084; http://dx.doi.org/10.1038/nri2604
   PubMed Web of Science ®Google Scholar
• Byrd A, Hoffmann SC, Jarahian M, Momburg F, Watzl C. Expression analysis of the ligands for the Natural Killer cell receptors NKp30 and NKp44. PLoS One 2007; 2:e1339; PMID:18092004; http://dx.doi.org/10.1371/journal.pone.0001339
   PubMedGoogle Scholar
• Pende D, Parolini S, Pessino A, Sivori S, Augugliaro R, Morelli L, Marcenaro E, Accame L, Malaspina A, Biassoni R et al. Identification and molecular characterization of NKp30, a novel triggering receptor involved in natural cytotoxicity mediated by human natural killer cells. J Exp Med 1999; 190:1505-16; PMID:10562324; http://dx.doi.org/10.1084/jem.190.10.1505
   PubMed Web of Science ®Google Scholar
• Ferlazzo G, Tsang ML, Moretta L, Melioli G, Steinman RM, Münz C. Human dendritic cells activate resting natural killer (NK) cells and are recognized via the NKp30 receptor by activated NK cells. J Exp Med 2002; 195:343-51; PMID:11828009; http://dx.doi.org/10.1084/jem.20011149
   PubMed Web of Science ®Google Scholar
• Vitale M, Della Chiesa M, Carlomagno S, Pende D, Aric∫ M, Moretta L, Moretta A. NK-dependent DC maturation is mediated by TNFalpha and IFNgamma released upon engagement of the NKp30 triggering receptor. Blood 2005; 106:566-71; PMID:15784725; http://dx.doi.org/10.1182/blood-2004-10-4035
   PubMed Web of Science ®Google Scholar
• Delahaye NF, Rusakiewicz S, Martins I, Ménard C, Roux S, Lyonnet L, Paul P, Sarabi M, Chaput N, Semeraro M, Minard-Colin V et al. Alternatively spliced NKp30 isoforms affect the prognosis of gastrointestinal stromal tumors. Nat Med 2011; 17:700-7; PMID:21552268; http://dx.doi.org/10.1038/nm.2366
   PubMed Web of Science ®Google Scholar
• Semeraro M, Rusakiewicz S, Minard-Colin V, Delahaye NF, Enot D, Vély F, Marabelle A, Papoular B, Piperoglou C, Ponzoni M et al. Clinical impact of the NKp30/B7-H6 axis in high-risk neuroblastoma patients. Sci Transl Med 2015; 7:283ra55; PMID:25877893; http://dx.doi.org/10.1126/scitranslmed.aaa2327
   PubMed Web of Science ®Google Scholar
• Arnon TI, Achdout H, Levi O, Markel G, Saleh N, Katz G, Gazit R, Gonen-Gross T, Hanna J, Nahari E et al. Inhibition of the NKp30 activating receptor by pp65 of human cytomegalovirus. Nat Immunol 2005; 6:515-23; PMID:15821739; http://dx.doi.org/10.1038/ni1190
   PubMed Web of Science ®Google Scholar
• Pogge von Strandmann, E, Simhadri VR, von Tresckow B, Sasse S, Reiners KS, Hansen HP, Rothe A, Böll B, Simhadri VL, Borchmann P et al. Human leukocyte antigen-B-associated transcript 3 is released from tumor cells and engages the NKp30 receptor on natural killer cells. Immunity 2007; 27:965-74; PMID:18055229; http://dx.doi.org/10.1016/j.immuni.2007.10.010
   PubMed Web of Science ®Google Scholar
• Brandt CS, Baratin M, Yi EC, Kennedy J, Gao Z, Fox B, Haldeman B, Ostrander CD, Kaifu T, Chabannon C et al. The B7 family member B7-H6 is a tumor cell ligand for the activating natural killer cell receptor NKp30 in humans. J Exp Med 2009; 206:1495-503; PMID:19528259; http://dx.doi.org/10.1084/jem.20090681
   PubMed Web of Science ®Google Scholar
• Fiegler N, Textor S, Arnold A, Rölle A, Oehme I, Breuhahn K, Moldenhauer G, Witzens-Harig M, Cerwenka A. Downregulation of the activating NKp30 ligand B7-H6 by HDAC inhibitors impairs tumor cell recognition by NK cells. Blood 2013; 122:684-93; PMID:23801635; http://dx.doi.org/10.1182/blood-2013-02-482513
   PubMed Web of Science ®Google Scholar
• Matta J, Baratin M, Chiche L, Forel JM, Cognet C, Thomas G, Farnarier C, Piperoglou C, Papazian L, Chaussabel D et al. Induction of B7-H6, a ligand for the Natural Killer cell activating receptor NKp30, in inflammatory conditions. Blood 122:394-404; PMID:23687088; http://dx.doi.org/10.1182/blood-2013-01-481705
   Web of Science ®Google Scholar
• Schlecker, E, Fiegler N, Arnold A, Altevogt P, Rose-John S, Moldenhauer G, Sucker A, Paschen A, von Strandmann EP, Textor S et al. Metalloprotease-mediated tumor cell shedding of B7-H6, the ligand of the natural killer cell-activating receptor NKp30. Cancer Res 2014; 74:3429-40; PMID:24780758; http://dx.doi.org/10.1158/0008-5472.CAN-13-3017
   PubMed Web of Science ®Google Scholar
• Adhikary S, Eilers M. Transcriptional regulation and transformation by Myc proteins. Nat Rev Mol Cell Biol 2005; 6:635-45; PMID:16064138; http://dx.doi.org/10.1038/nrm1703
   PubMed Web of Science ®Google Scholar
• Lüscher B. MAD1 and its life as a MYC antagonist: An update. Euro J Cell Biol 2012; 91:506-514; PMID:21917351; http://dx.doi.org/10.1016/j.ejcb.2011.07.005
   PubMed Web of Science ®Google Scholar
• Albihn A, Johnsen JI, Henriksson MA. MYC in oncogenesis and as a target for cancer therapies. Adv Cancer Res 2010; 107:163-224; PMID:20399964; http://dx.doi.org/10.1016/S0065-230X(10)07006-5
   PubMed Web of Science ®Google Scholar
• Dalla-Favera R, Bregni M, Erikson J, Patterson D, Gallo RC, Croce CM. Human c-myc onc gene is located on the region of chromosome 8 that is translocated in Burkitt lymphoma cells. Proc Natl Acad Sci U S A 1982; 79:7824-7; PMID:6961453; http://dx.doi.org/10.1073/pnas.79.24.7824
   PubMed Web of Science ®Google Scholar
• Taub R, Kirsch I, Morton C, Lenoir G, Swan D, Tronick S, Aaronson S, Leder P. Translocation of the c-myc gene into the immunoglobulin heavy chain locus in human Burkitt lymphoma and murine plasmacytoma cells. Proc Natl Acad Sci U S A 1982; 79:7837-41; PMID:6818551; http://dx.doi.org/10.1073/pnas.79.24.7837
   PubMed Web of Science ®Google Scholar
• Seeger RC, Brodeur GM, Sather H, Dalton A, Siegel SE, Wong KY, Hammond D. Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N Engl J Med 1985; 313:1111-6; PMID:4047115; http://dx.doi.org/10.1056/NEJM198510313131802
   PubMed Web of Science ®Google Scholar
• Wong PP, Miranda F, Chan KV, Berlato C, Hurst HC, Scibetta AG. Histone demethylase KDM5B collaborates with TFAP2C and Myc to repress the cell cycle inhibitor p21(cip) (CDKN1A). Mol Cell Biol 2012; 32:1633-44; PMID:22371483; http://dx.doi.org/10.1128/MCB.06373-11
   PubMed Web of Science ®Google Scholar
• Boyd KE, Wells J, Gutman J, Bartley SM, Farnham PJ. c-Myc target gene specificity is determined by a post-DNAbinding mechanism. Proc Natl Acad Sci U S A 1998; 95:13887-92; PMID:9811896; http://dx.doi.org/10.1073/pnas.95.23.13887
   PubMed Web of Science ®Google Scholar
• Vita M, Henriksson M. The Myc oncoprotein as a therapeutic target for human cancer. Semin Cancer Biol 2006; 16:318-30; PMID:16934487; http://dx.doi.org/10.1016/j.semcancer.2006.07.015
   PubMed Web of Science ®Google Scholar
• Textor S, Fiegler N, Arnold A, Porgador A, Hofmann TG, Cerwenka A. Human NK cells are alerted to induction of p53 in cancer cells by upregulation of the NKG2D ligands ULBP1 and ULBP2. Cancer Res 71, 5998-6009; PMID:21764762; http://dx.doi.org/10.1158/0008-5472.CAN-10-3211
   PubMed Web of Science ®Google Scholar
• Huergo-Zapico L, Acebes-Huerta A, López-Soto A, Villa-Álvarez M, Gonzalez-Rodriguez AP, Gonzalez S. Molecular Bases for the Regulation of NKG2D Ligands in Cancer. Front Immunol 2014; 5:106; PMID:24711808; http://dx.doi.org/10.3389/fimmu.2014.00106
   PubMed Web of Science ®Google Scholar
• Unni AM, Bondar T, Medzhitov R. Intrinsic sensor of oncogenic transformation induces a signal for innate immunosurveillance. Proc Natl Acad Sci U S A 2008; 105, 1686-91; PMID:18223157; http://dx.doi.org/10.1073/pnas.0701675105
   PubMed Web of Science ®Google Scholar
• Liu XV, Ho SS, Tan JJ, Kamran N, Gasser S. Ras activation induces expression of Raet1 family NK receptor ligands. J Immunol 2012; 189:1826-34; PMID:22798674; http://dx.doi.org/10.4049/jimmunol.1200965
   PubMed Web of Science ®Google Scholar
• Boissel N, Rea D, Tieng V, Dulphy N, Brun M, Cayuela JM, Rousselot P, Tamouza R, Le Bouteiller P, Mahon FX et al. BCR/ABL oncogene directly controls MHC class I chain-related molecule A expression in chronic myelogenous leukemia. J Immunol 2006; 176:5108-16; PMID:16585609; http://dx.doi.org/10.4049/jimmunol.176.8.5108
   PubMed Web of Science ®Google Scholar
• Okita R, Mougiakakos D, Ando T, Mao Y, Sarhan D, Wennerberg E, Seliger B, Lundqvist A, Mimura K, Kiessling R. HER2/HER3 signaling regulates NK cell-mediated cytotoxicity via MHC class I chain-related molecule A and B expression in human breast cancer cell lines. J Immunol 2012; 188:2136-45; PMID:22301547; http://dx.doi.org/10.4049/jimmunol.1102237
   PubMed Web of Science ®Google Scholar
• Nanbakhsh A, Pochon C, Mallavialle A, Amsellem S, Bourhis JH, Chouaib S. c-Myc regulates expression of NKG2D ligands ULBP1/2/3 in AML and modulates their susceptibility to NK-mediated lysis. Blood 2014; 123:3585-95; PMID:24677544; http://dx.doi.org/10.1182/blood-2013-11-536219
   PubMed Web of Science ®Google Scholar
• Melero I, Rouzaut A, Motz GT, Coukos G. T-cell and NK-cell infiltration into solid tumors: a key limiting factor for efficacious cancer immunotherapy. Cancer Discov 2014; 4:522-6; PMID:24795012; http://dx.doi.org/10.1158/2159-8290.CD-13-0985
   PubMed Web of Science ®Google Scholar
• Sconocchia G, Eppenberger S, Spagnoli GC, Tornillo L, Droeser R, Caratelli S, Ferrelli F, Coppola A, Arriga R, Lauro D et al. NK cells and T cells cooperate during the clinical course of colorectal cancer. Oncoimmunology 2014; 3:e952197; PMID:25610741; http://dx.doi.org/10.4161/21624011.2014.952197
   PubMed Web of Science ®Google Scholar
• Felsher DW, Bishop JM. Reversible tumorigenesis by MYC in hematopoietic lineages. Mol Cell 1999; 4:199-207; PMID:10488335; http://dx.doi.org/10.1016/S1097-2765(00)80367-6
   PubMed Web of Science ®Google Scholar
• Guo J, Parise RA, Joseph E, Egorin MJ, Lazo JS, Prochownik EV, Eiseman JL. Efficacy, pharmacokinetics, tisssue distribution, and metabolism of the Myc-Max disruptor, 10058-F4 [Z,E]-5-[4-ethylbenzylidine]-2-thioxothiazolidin-4-one, in mice. Cancer Chemother Pharmacol 2009; 63:615-25; PMID:18509642; http://dx.doi.org/10.1007/s00280-008-0774-y
   PubMed Web of Science ®Google Scholar
• Delmore JE, Issa GC, Lemieux ME, Rahl PB, Shi J, Jacobs HM, Kastritis E, Gilpatrick T, Paranal RM, Qi J et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 2011; 146:904-17; PMID:21889194; http://dx.doi.org/10.1016/j.cell.2011.08.017
   PubMed Web of Science ®Google Scholar
• Mertz JA, Conery AR, Bryant BM, Sandy P, Balasubramanian S, Mele DA, Bergeron L, Sims RJ 3rd. Targeting MYC dependence in cancer by inhibiting BET bromodomains. Proc Natl Acad Sci U S A 2011; 108:16669-74; PMID:21949397; http://dx.doi.org/10.1073/pnas.1108190108
   PubMed Web of Science ®Google Scholar
• Tam YK, Miyagawa B, Ho VC, Klingemann HG. Immunotherapy of malignant melanoma in a SCID mouse model using the highly cytotoxic natural killer cell line NK-92. J Hematother 1999; 8:281-90; PMID:10417052; http://dx.doi.org/10.1089/106161299320316
   PubMedGoogle Scholar
• Dreidax D, Bannert S, Henrich KO, Schröder C, Bender S, Oakes CC, Lindner S, Schulte JH, Duffy D, Schwarzl T et al. p19-INK4d inhibits neuroblastoma cell growth, induces differentiation and is hypermethylated and downregulated in MYCN-amplified neuroblastomas. Hum Mol Genet 2014; 23:6826-37; PMID:25104850; http://dx.doi.org/10.1093/hmg/ddu406
   PubMed Web of Science ®Google Scholar
• Muth D, Ghazaryan S, Eckerle I, Beckett E, Pöhler C, Batzler J, Beisel C, Gogolin S, Fischer M, Henrich KO et al. Transcriptional repression of SKP2 is impaired in MYCN-amplified neuroblastoma. Cancer Res 2010; 70:3791-802; PMID:20424123; http://dx.doi.org/10.1158/0008-5472.CAN-09-1245
   PubMed Web of Science ®Google Scholar
• Wang W, Malcolm BA. Two-stage PCR protocol allowing introduction of multiple mutations, deletions and insertions using QuikChange Site-Directed Mutagenesis. Biotechniques 1999; 26:680-2; PMID:10343905
   PubMed Web of Science ®Google Scholar
• Hocke GM, Cui MZ, Ripperger JA, Fey GH. Regulation of the rat alpha 2 macroglobulin gene by interleukin 6 and leukemia inhibitory factor. Folia Histochem Cytobiol 1992; 30:137-9; PMID:1284662
   PubMed Web of Science ®Google Scholar
• Peifer M, Hertwig F, Roels F, Dreidax D, Gartlgruber M, Menon R, Krämer A, Roncaioli JL, Sand F, Heuckmann JM et al. Telomerase activation by genomic rearrangements in high-risk neuroblastoma. Nature 2015; 526:700-4; PMID:26466568; http://dx.doi.org/10.1038/nature14980
   PubMed Web of Science ®Google Scholar
• Duffy DJ, Krstic A, Schwarzl T, Higgins DG, Kolch W. GSK3 inhibitors regulate MYCN mRNA levels and reduce neuroblastoma cell viability through multiple mechanisms, including p53 and Wnt signaling. Mol Cancer Ther 2014; 13:454-67; PMID:24282277; http://dx.doi.org/10.1158/1535-7163.MCT-13-0560-T
   PubMed Web of Science ®Google Scholar
• Zhang W, Yu Y, Hertwig F, Thierry-Mieg J, Zhang W, Thierry-Mieg D, Wang J, Furlanello C, Devanarayan V, Cheng J et al. Comparison of RNA-seq and microarray-based models for clinical endpoint prediction. Genome Biol 2015; 16:133; PMID:26109056; http://dx.doi.org/10.1186/s13059-015-0694-1
   PubMed Web of Science ®Google Scholar